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Floating-Harbor syndrome (FHS) is a rare condition characterized by short stature, delayed osseousmaturation, expressive-language defi-
cits, and a distinctive facial appearance. Occurrence is generally sporadic, although parent-to-child transmission has been reported on
occasion. Employing whole-exome sequencing, we identified heterozygous truncating mutations in SRCAP in five unrelated individuals
with sporadic FHS. Sanger sequencing identified mutations in SRCAP in eight more affected persons. Mutations were de novo in all six
instances in which parental DNA was available. SRCAP is an SNF2-related chromatin-remodeling factor that serves as a coactivator for
CREB-binding protein (CREBBP, better known as CBP, the major cause of Rubinstein-Taybi syndrome [RTS]). Five SRCAPmutations, two
of which are recurrent, were identified; all are tightly clustered within a small (111 codon) region of the final exon. These mutations are
predicted to abolish three C-terminal AT-hook DNA-bindingmotifs while leaving the CBP-binding and ATPase domains intact. Our find-
ings show that SRCAP mutations are the major cause of FHS and offer an explanation for the clinical overlap between FHS and RTS.Floating-Harbor syndrome (FHS [MIM 136140]) is a rare
condition characterized by short stature, delayed osseous
maturation, language deficits, and a distinctive facial
appearance. The dysmorphic features typical of this
disorder include a triangular face, short philtrum, wide
mouth with a thin vermilion border of the upper lip, and
long nose with a narrow bridge, broad base, full tip, and
low-hanging columella.1–4 Some degree of intellectual or
learning disability is present in most individuals, and
language (both receptive and expressive) is typically
more severely affected. The name ‘‘Floating Harbor’’ is
a portmanteau of Boston Floating Hospital and Harbor
General Hospital (Torrance, CA), the two institutions
from which the initial case reports originated.1,2 Of the
50 or so cases of FHS in the literature, the majority are
sporadic, although four reported instances of parent-to-
child transmission suggest that this is an autosomal-domi-
nant disorder in at least some instances.4–7 Some authors
have highlighted the clinical overlap between FHS and
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with low-hanging columella, a thin vermilion border of
the upper lip, and anomalous thumbs).3,7 Despite the
recognition of FHS as a distinct clinical entity more than
25 years ago, no causative mutations have been identified
to date.
To identify the genetic basis of FHS, we assembled
a cohort of 13 unrelated probands, three of whom were
previously reported.4 The clinical details of these individ-
uals are presented in Table 1 and Figure 1. To identify
FHS-causing mutations, we performed exome capture
and high-throughput sequencing of five unrelated affected
persons (probands 1–5). Approval of the study design was
obtained from the institutional research ethics board
(Children’s Hospital of Eastern Ontario), and free and
informed consent was obtained from each study subject
(or parent, if appropriate) prior to enrollment. We per-
formed exome target enrichment by using the Agilent
SureSelect 50 Mb All Exon Kit, and sequencing (Illumina
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Table 1. Phenotype of Floating-Harbor Syndrome Probands with SRCAP Mutationsa
Proband 1 2 3 4 5 6 7 8 9 10 11 12 13
Mutation
(cDNA)
c.7330C>T c.7330C>T c.7330C>T c.730C>T c.7549delC c.7330C>T c.7330C>T c.7330C>T c.7303C>T c.7303C>T c.7303C>T c.7218_
7219delTC
c.7316dupC
Alteration
(protein)
p.Arg2444* p.Arg2444* p.Arg2444* p.Arg2435* p.Gln2517fs*5 p.Arg2444* p.Arg2444* p.Arg2444* p.Arg2435* p.Arg2435* p.Arg2435* p.Gln2407fs*35 p.Ala2440fs*3
Inheritance unknown unknown unknown de novo de novo de novo de novo unknown unknown unknown unknown de novo de novo
Sex M F M M M M M F M M M M M
Ethnicity French mixed
European
mixed
European
Finnish German
and Mexican
Brazilian German Caucasian Caucasian Brazilian Brazilian Chinese Polish
Paternal
age (year)
28 43 29 35 39 32 44 40 34 41 40 40 35
Gestation
(weeks)
40 40 38 37 39 40 39 31 41 39 40 40 41
Birth
weight (g)
3,040
(0.7 SD)
3,060
(0.6 SD)
2,400
(1.7 SD)
2,620
(0.5 SD)
2,515
(2.2 SD)
2,555
(1.8 SD)
2,430
(2.4 SD)
1,655
(0 SD)
2,900
(1.0 SD)
2,550
(1.8 SD)
2,030
(3.1 SD)
2,800
(1.1 SD)
2,730
(1.5 SD)
Age at
diagnosis
3 years 10 years 15 months 11 years 4 years,
3 months
3 years,
3 months
4 years,
4 months
4 years 11 months 7 years,
5 months
8 years 10 years 35 months
ALA 8 years 12 years 12 years 11 years 4 years,
3 months
4 years 4 years,
4 months
10 years,
5 months
11 years 19 years 19 years,
7 months
11 years 7 years, 5 months
Head
circumference
(cm) ALA
54 (þ1 SD) 0 SD 53 (1 SD) 53.5 (0 SD) 48.5
(1.7 SD)
48 (2 SD) 50 (þ0.7 SD) 49.5 (1 SD) 50.5 (2 SD) 52
(2.5 SD)
56 (0 SD) 53 (0 SD) 51.5 (0.5 SD)
Weight (kg)
ALA
25.5
(0 SD)
35.6
(0.8 SD)
N/R 22.4
(3.2 SD)
11
(3.4 SD)
12
(2.5 SD)
12.5
(2.4 SD)
19.3
(3.3 SD)
20
(4.2 SD)
37.6
(5.3 SD)
62.1
(0.7 SD)
35 (0 SD) 20 (1.4 SD)
Height (cm)
ALA
123
(0.8 SD)
133.5
(2.2 SD)
134.8
(2.0 SD)
122
(3.1 SD)
86.5
(4.3 SD)
89.8
(3.2 SD)
90
(3.6 SD)
118.5
(3.5 SD)
116.8
(3.9 SD)
145.5
(4.1 SD)
148
(3.8 SD)
139 (0.6 SD) 111 (2.5 SD)
Age at
puberty
N/A 12 years N/A N/A N/A N/A N/A N/A Pubertal age
14 years at
CA 11 years
N/R N/R 10 years N/A
Prepubertal
height
0.8 SD 2.2 SD 2.0 SD 3.1 SD 4.4 SD 3.2 SD 3.6 SD 3.5 SD N/R N/R N/R 3 SD 2.5 SD
BA versus CA BA 2.5 years
at CA
7.5 years
BA 2 years,
6 months
at CA 5 years,
7 months;
BA 11 years at
CA 9 years,
9 months
BA 8 years at
CA 11 years
BA 2 years at
CA 4 years,
8 months;
BA 9 years at
CA10 years,
8 months
BA 1 year at
CA 2 years,
11 months
BA 1 year at
CA 3 years
BA 3 years at
CA 4 years
BA 1 year at
CA 5 years
BA 3–6 months
at CA 1 year
BA 2 years,
8 months at
CA 7 years
BA 3 years
at CA 7 years
BA 10 years,
6 months at
CA 11 years,
4 months
BA 8 months
at CA 2 years,
8 months
Triangular
face
þ þ þ þ þ N/R - þ þ þ þ þ þ
Distinctive
nose
þ þ þ þ þ þ þ þ þ þ þ þ þ
Low-hanging
columella
þ þ þ þ þ þ þ þ þ þ þ þ þ
(Continued on next page)
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Table 1. Continued
Proband 1 2 3 4 5 6 7 8 9 10 11 12 13
Short
philtrum
þ þ þ þ þ þ þ þ þ - þ - þ
Thin upper
vermilion
border
þ þ þ þ - - þ þ þ - - þ þ
Wide mouth þ - þ þ þ/ þ þ þ þ þ þ þ þ
Low-set ears þ þ - þ þ - þ þ þ - - þ þ
Broad thumbs - þ - þ þ þ - N/R N/R N/R þ þ þ
Broad
fingertips
- þ þ þ N/R N/R - N/R þ N/R þ þ þ
Brachydactyly - þ þ þ - fifth toes - þ - N/R þ þ þ
Clinodactyly - N/R radial deviation
fifth distal
phalanx
þ þ - - þ þ N/R þ þ þ
Other
skeletal
N/R N/R dislocated
radial head,
11 rib pairs
N/R short fifth
metacarpal
N/R clavicular
hypoplasia
kyphoscoliosis dysplastic hips 11 rib pairs,
ivory epiphyses
in distal
phalanges
short middle
phalanges of
second and
fifth fingers
short first
metacarpal
short fifth
metacarpal
Dental
issues
N/R N/R maxillary
retrusion,
underbite
caries,
microdontia
N/R N/R N/R caries, delayed
loss of primary
teeth
N/R N/R normal caries,
microdontia,
underbite
N/R
Other
health
issues
hypospadias,
celiac disease
hydro-
nephrosis,
nephro-
calcinosis,
recurrent
otitis media
aortic
coarctation
(mild)
cryptorchidism,
hyperopia,
conductive
hearing loss
hyperopia ASD,
hyperopia,
unilateral
renal
pelviectasis
mesocardia,
persistent left
superior vena
cava, conductive
hearing loss
constipation bilateral
inguinal hernia,
cryptorchidism,
VPI, hearing loss
posterior
urethral valves,
umbilical hernia
strabismus bilateral
epididymal
cysts, left
varicocele
unilateral
cleft lip,
cryptorchidism
Intellectual
development
borderline
normal
normal borderline
normal
borderline
normal
normal moderate
delay
borderline
normal
mild intellectual
disability
moderately
severe learning
disability
significant
intellectual
disability
intellectual
disability
borderline
normal
mild
intellectual
disability
Expressive
language
delay
delay moderate
delay
moderate
delay
impairment borderline
normal,
bilingual
moderate
delay
moderate
delay
severe delay moderate
delay
some words moderate
delay
moderate
delay
moderate
delay
Education mainstream
with support
mainstream
with support
mainstream
with support
special school mainstream N/A mainstream
with support
modified
classroom
special school special school special school modified
classroom
mainstream
with support
Microarray
findings
and (type)
normal
(44K)
normal
(Affymetrix
2.7M)
normal
(180K
Agilent)
normal (105K) 7q31dup
(paternally
inherited)
Xp22.31dup
(maternally
inherited)
N/A N/A N/A N/A normal 22q11 normal
(Agilent 6.1)
normal
(244K Agilent)
Reference White et al,4
person 10
White et al,4
person 9
this report this report this report this report this report this report White et al,4
person 8
this report this report this report this report
Numbering of mutations is relative to NM_006662.2 (gene) and NP_006653 (protein). Abbreviations are as follows: ALA, at last assessment; N/A, Not Applicable; N/R, Not Reported;þ, Feature Present; -, Feature Absent; SD,
standard deviations; BA, bone age; CA, chronological age; ASD, atrial septal defect; and VPI, velopharyngeal incompetence.
a This table summarizes the clinical findings in all study participants. Five participants (discovery cohort; individuals 1–5) underwent exome sequencing. Mutations in individuals 6–13 (validation cohort) were identified with
Sanger sequencing.
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Figure 1. Floating-Harbor Syndrome Due to SRCAP Mutations
Clinical photos depicting 9 of 13 unrelated FHS probands with a confirmed SRCAPmutation are shown with the characteristically trian-
gular face, long eyelashes, typical nose (long and narrow nasal bridge, broad base, full tip, and low-hanging columella), short philtrum,
widemouth, thin vermilion border of the upper lip, short chin, and low-set, posteriorly rotated ears. Clinical details concerning all study
participants are presented in Table 1.
(A) Individual 1. Age 3 years; age 8 years.
(B) Individual 3. Age 3 years, 7 months; age 11 years, 5 months.
(C) Individual 4. Age 4 years, 6 months.
(D) Individual 8. Age 4 years; age 10 years, 5 months.
(E) Individual 9. Age 11 years.
(F) Individual 10. Age 15 months; age 19 years.
(G) Individual 11. Age 19 years, 7 months.
(H) Individual 12. Age 4 years.
(I) Individual 13. Age 3 years; age 7 years, 5 months.
Table 2. Variant Analysis in Floating-Harbor Syndrome Probands
Any X of five individuals 1 2 3 4 5
Number of genes containing missense,
nonsense, insertion, deletion,
or splice-site variants
2,375 307 48 8 2
Allele frequency %1% in dbSNP131
and 1000 Genomes; not represented
in 270 local exomes
1,178 70 3 SRCAP SRCAPper sample. Readswere preprocessed (trimmed) and aligned
to hg19 (seeWeb Resources for list of tools). We used an in-
house annotation pipeline to identify coding and splice-
site variants that met a minimum quality threshold (i.e.,
R20% of reads supported the variant). Next, we filtered
the variants to exclude common polymorphisms (>1%
minor-allele frequency) represented in dbSNP131, in the
1000 Genomes pilot release, or in 270 exomes sequenced
for individuals with unrelated disorders at our center.
Presuming FHS to be an autosomal-dominant condition,
we identified genes containing a single rare variant in each
of several probands in a combinatorial fashion. Table 2 lists
the numbers of potential candidate genes containing rare
variants in any n probands as n is increased. Of five
sequenced individuals with classic FHS, we noted that all
contained heterozygous truncating variants clustered in
the final (34th) exon of a single gene, SRCAP (encoding
SNF2-related CREBBP activator protein). To confirm SRCAP
as the gene mutated in FHS, we identified SRCAP exon 34
mutations with Sanger sequencing in a validation cohort
of eight more unrelated probands (Table 1 and Figure 2;
Figure S1, available online). All of thesemutations are trun-
cating (nonsense or frameshift) alleles, tightly clustered
between codons 2,407 and 2,517; none are represented in
dbSNP131, 1000 Genomes, or the National Heart, Lung,The Americaand Blood Institute (NHLBI) Exome Variant Server (see
Web Resources). Two mutations in particular, c.7330C>T
(NM_006662.2) (p.Arg2444* [NP_006653]) in six individ-
uals and c.7303C>T (p.Arg2435*) in four individuals,
accounted for the largemajority of mutations. FHS-causing
mutations were shown to be de novo in all six instances in
which parental DNA samples were available.
SRCAP encodes a switch/sucrose nonfermentable (SWI/
SNF)-type chromatin-remodeling ATPase identified in
a two-hybrid screen for interacting partners of CREB-
bindingprotein (CREBBP,hereafter calledCBP).8 In reporter
assays, SRCAP is a potent coactivator for CREB and
CBP-mediated transcription.8,9 In transgenic Drosophila,
exogenous SRCAP colocalizes with transcriptionally active
chromatin and augments CBP’s presence at these sites.10n Journal of Human Genetics 90, 308–313, February 10, 2012 311
Figure 2. Locations of FHS-Causing Mutations within SRCAP
(A) Intron-exon structure of SRCAP. Exon 34 mutation cluster is indicated by a red bar.
(B) Domain architecture of SRCAP8–10 indicates amino acid positions of recognized domains and FHS-causing mutations. All probands
are heterozygous for truncating mutations at the positions shown. The ATPase domain of SRCAP is divided into two sections, one con-
taining conserved motifs I-IV and one containing V-VI. The following abbreviation is used: HSA, Helicase-SANT-associated domain.Affinity-purified SRCAP precipitates as a large complex that
catalyzes ATP-dependent substitution of the variant
histone H2A.Z into nucleosomes.11 This activity has been
confirmed by knockdown experiments with natural
promoters, and it is correlated with in vivo target-gene
expression.12 Separately, SRCAP has also been shown to
transduce signals belonging to the nuclear (steroid)
hormone receptor and Notch pathways, indicating that it
has diverse roles in gene expression.10,13
In keeping with its multiple coactivator roles, SRCAP
contains several discrete functional domains.8–10 These
domains include an SNF2-like ATPase, an N-terminal HSA
(Helicase-SANT-associated) domain, and three C-terminal
AT-hook DNA-bindingmotifs; the CBP interaction domain
of SRCAP is located centrally (Figure 2). Given the structure
of SRCAP, the nonrandom clustering of truncating muta-
tions seen in our study participants is strongly suggestive
of a dominant-negative disease mechanism due to loss of
one or more critical domain(s), for instance the three
C-terminal AT-hook motifs. Several more arguments sup-
port this. First, in reporter assays, the major transactivation
function of SRCAP is located in a 655 residue C-terminal
fragment abolished by FHS-causing truncations.9 Second,
expression of a construct solely consisting of the CBP inter-
action domain of SRCAP strongly inhibits CREB-mediated
transactivation in a dominant-negative fashion.9 Third,
the Database of Genomic Variants (see Web Resources)
contains two HapMap control individuals who bear a
208 kb deletion copy-number variation (#2,209) contain-
ing SRCAP and nine adjacent genes and who have no re-
ported phenotype.
In general, the phenotype of persons with SRCAP muta-
tions is concordant with earlier clinical descriptions of FHS
(Table 1 and Figure 1), and nearly all individuals have
short stature and expressive-language impairment. Despite
the remarkable similarity among mutations seen in our
study subjects, cognitive outcomes ranging from ‘‘normal’’
to ‘‘significant intellectual disability’’ were reported. It is312 The American Journal of Human Genetics 90, 308–313, Februaryunclear whether genetic modifier(s) and/or currently
unidentified environmental factors are responsible. Many
of our study subjects had additional systemic malforma-
tions, particularly genitourinary (eight individuals) and
cardiac (three individuals) malformations. Again, geno-
type-phenotype correlations explaining these features are
lacking. Given that FHS is a dominant condition exhibit-
ing a high de novo mutation rate, one might expect
a paternal age effect to be present, and indeed the mean
paternal age of the affected individuals was advanced
(36.9 years; range: 29–44 years).
Importantly, our findings suggest a basis for the long-
recognized phenotypic overlap between FHS and RTS,
the latter of which is caused by alterations in CBP or its
homolog, p300.14–16 Because alterations in both CBP and
SRCAP are expected to produce widespread target-gene
dysregulation, further studies are needed before we can
determine which transcriptional targets are primarily
responsible for each phenotype and whether any of these
might be valid therapeutic targets. The availability of
a molecular test for FHS will greatly improve the reliability
of a formerly challenging clinical diagnosis. Historically,
a diagnosis of FHS has relied upon the presence of typical
facial features because many other key findings (e.g., short
stature and language impairment) are nonspecific. The
advent of molecular diagnosis for this condition will allow
us to gain a better appreciation of the true prevalence and
phenotypic spectrum of FHS.
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